Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Case Report: A Rare But Severe Complication of Dermatomyositis

Akrithi Udupa, MD, Paul McIntosh, MD, Thomas J. Cummings, MD, & Lisa Criscione-Schreiber, MD, Med  |  Issue: May 2021  |  May 13, 2021

Discussion

This is a case of anti-TIF1-γ positive paraneoplastic acute hemorrhagic dermatomyositis, an uncommon yet severe complication of dermatomyositis. As shown in Table 1, at least 16 adult cases of acute hemorrhagic dermatomyositis have been reported.4-18 The majority of these patients were middle aged, with approximately equal distribution among men and women.

Table 1

Legend: ANA, anti-nuclear antibody; AMA, anti-mitochondrial antibody; ASMA, anti-smooth muscle antibody; Anti-TIF1-γ, anti-transcription intermediary factor 1-γ; AZA, azathioprine; BP, blood pressure; CK, creatine kinase; CSA, cyclosporin A; CYC, cyclophosphamide; Hgb, hemoglobin; IVIG, intravenous immunoglobulin; MMF, mycophenolate mofetil; RF, rheumatoid factor; RNP, ribonucleoprotein; SCM, sternocleidomastoid; VS, vital signs

(Click for larger image) Table 1

(Click for larger image) Table 1

(Click for larger image) Table 1 continued from page

Legend: ANA, anti-nuclear antibody; AMA, anti-mitochondrial antibody; ASMA, anti-smooth muscle antibody; Anti-TIF1-γ, anti-transcription intermediary factor 1-γ; AZA, azathioprine; BP, blood pressure; CK, creatine kinase; CSA, cyclosporin A; CYC, cyclophosphamide; Hgb, hemoglobin; IVIG, intravenous immunoglobulin; MMF, mycophenolate mofetil; RF, rheumatoid factor; RNP, ribonucleoprotein; SCM, sternocleidomastoid; VS, vital signs

Although the past medical histories and clinical contexts differ slightly among these patients, only one was reported as having a concurrent malignancy.18 Most were newly diagnosed with dermatomyositis and subsequently developed atraumatic painful intramuscular hematomas, some of which were hemodynamically significant. All events occurred following administration of systemic glucocorticoids, and most events occurred following prophylactically or therapeutically dosed anticoagulation.

Some patients were treated with IVIG either before or after the hemorrhagic event, and a few were treated with disease-modifying anti-rheumatic drugs (DMARDs) either before, during or after acute hematoma formation.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Comprehensive autoimmune serologies were either not performed or not described in a majority of these case reports; of those reported, a positive ANA was seen in four patients, Sjögren’s syndrome-related antigen A (SSA) 52 kDa antibody in two patients, and Krebs von den Lungen 6 (KL-6) antibody in two patients. Apart from our case, only two other reports identified the presence of myositis-specific autoantibodies.14,16

Even with prompt recognition, acute hemorrhagic myositis can cause abrupt hemodynamic collapse and rapid progression to death. Aside from the inherent microvasculopathy of dermatomyositis, nearly all patients reported in the literature received either prophylactic or therapeutic doses of anticoagulation ahead of having a hemorrhagic event; this finding underscores the complex safety concerns surrounding anticoagulation in often immobile patients with underlying malignancies.

All patients reported in the literature seem to have developed hematomas while receiving systemic glucocorticoids and often did not respond to an escalation in steroid dose, calling into question the utility of immunosuppression in this clinical context.

Apart from vital sign changes and a decline in hemoglobin, the earliest diagnostic clue appears to be the acute onset of localized pain, which can be out of proportion to exam.

Apart from vital sign changes and a decline in hemoglobin, the earliest diagnostic clue appears to be the acute onset of localized pain, which can be out of proportion to exam. As in our case, a rapid rise in CK could also herald the presence of an intramuscular hematoma. Further research is needed to clarify whether the presence of certain autoantibodies, especially myositis-specific autoantibodies, confer a higher risk of developing hemorrhagic complications; this ultimately may help further define the clinical phenotypes associated with myositis-specific autoantibodies and aid in timely recognition and treatment.

In conclusion, acute hemorrhagic dermatomyositis is an unexpected yet potentially fatal complication of dermatomyositis. Further study is needed to understand its pathogenesis, identify those at highest risk, recognize early diagnostic clues and establish effective treatments.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:ConditionsMyositis Tagged with:case reportdermatomyositis (DM)hemorrhagic dermatomyositis

Related Articles

    New Tools for Myositis Diagnosis, Classification & Management

    April 15, 2019

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

    Autoantibodies in Autoimmune Myopathy

    Autoantibodies in Autoimmune Myopathy

    September 18, 2017

    In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical pheno­types in IIMs. Scientists continue to learn more about how these auto­antibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…

    Tashatuvango / shutterstock.com

    Myositis-Specific Antibodies Identified

    January 16, 2020

    The idiopathic inflammatory myopathies (IIM) encompass eight categories: 1) dermatomyositis (DM) in adults, 2) juvenile dermatomyositis, 3) amyopathic DM, 4) cancer-associated DM, 5) polymyositis, 6) immune-mediated necrotizing myopathy, 7) inclusion body myositis, and 8) overlap myositis.1 These categories help classify the myopathies based on clinical and histologic features. The incidence of IIM is estimated at…

    Myositis Mysteries

    January 1, 2008

    Why isn’t my myositis patient getting better?

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences